Therapeutics News and Research

RSS

Lisofylline drug improves type 2 insulin action; reduces harm of fat in preclinical study

Results of a preclinical study involving DiaKine Therapeutics' lead drug candidate Lisofylline (LSF) indicate the compound may reduce two key risk factors for type 2 diabetes.

23 Jan 2009

Topical treatment wipes out herpes with RNAi

Whether condoms or abstinence, most efforts to prevent sexually transmitted diseases have a common logic: keep the pathogen out of your body altogether.

21 Jan 2009

Slices of living human brain tissue are helping scientists identify new stroke therapies

Slices of living human brain tissue are helping scientists learn which drugs can block the waves of death that engulf and engorge brain cells following a stroke.

21 Jan 2009

Biotech venture seeks West Nile virus treatment from antibodies in geese

Rich Glynn, a straight-talking entrepreneur from South Dakota, doesn't mince words when explaining why a partnership between his fledgling goose operation and the University of North Dakota is a match made in heaven.

21 Jan 2009

Mutant host cell protein sequesters critical HIV-1 element

Scientists have identified a new way to inhibit a molecule that is critical for HIV pathogenesis.

19 Jan 2009

Polymer nanoparticle for oral anticancer drug delivery

One of the problems that cancer patients face is that many of the most potent anticancer therapies can be administered only by injection, which means that cancer patients must travel to receive their medication. But thanks to a new type of nanoparticle developed by researchers at the Johns Hopkins University School of Medicine, future cancer patients may be able to receive their medication in pill form.

18 Jan 2009

Cell Therapeutics targeting potential Zevalin label expansion,

In meetings held in association with the JP Morgan Healthcare Conference in San Francisco, Cell Therapeutics, Inc. (CTI) reviewed 2009 targeted milestones and 2008 accomplishments.

15 Jan 2009

Advaxis wins European patent case involving Lovaxin-C vaccine

The European Patent Court in Munich, Germany has ruled in favor of Advaxis Incorporated and reversed a patent challenge made by Anza Therapeutics, Inc., formerly Cerus Corp.

15 Jan 2009

Oncolytics Biotech issued new U.S. patent

Oncolytics Biotech Inc. has announced that it has been granted its 31st U.S. Patent, # 7,476,382, entitled "Reovirus for the Treatment of Neoplasia." The patent includes claims to pharmaceutical compositions containing reovirus.

13 Jan 2009

Thumbs down by experts on plans to make certain meds OTC

Government plans to make certain prescription-only drugs for common problems available over the counter have overwhelmingly been given the thumbs down by healthcare professionals, reveals a survey of readers of the influential Drug and Therapeutics Bulletin ( DTB ).

13 Jan 2009

Question marks over herbal remedies for menopausal symptoms

There is no strong evidence either way for several herbal remedies commonly taken to relieve troublesome menopausal symptoms, concludes the January issue of the Drug and Therapeutics Bulletin ( DTB ).

13 Jan 2009

Gene therapy kills brain tumors through selective recruitment of immune cells

Scientists seeking to harness the power of the immune system to eradicate brain tumors face two major hurdles: recruiting key immune cells called dendritic cells into areas of the brain where they are not naturally found and helping them recognize tumor cells as targets for attack.

13 Jan 2009

Wyeth and Santaris Pharma to collaborate on RNA-based medicines

Wyeth Pharmaceuticals, a division of Wyeth, and Santaris Pharma have announced that the companies have entered into a worldwide strategic alliance to discover, develop and commercialize new medicines based on Santaris Pharma's proprietary Locked Nucleic Acid (LNA) drug platform, which allows specific targeting and regulation of microRNAs (miRNAs) and messenger RNAs (mRNAs) as a means to affect gene expression mediated by the targeted RNAs.

12 Jan 2009

Discovery of first gender-linked susceptibility gene for late-onset Alzheimer's disease

In the Jan. 11 online edition of Nature Genetics, they report the results of their two-stage genome-wide association study of patients with Alzheimer's disease. The research showed that women who inherited two copies of a variant in the PCDH11X gene, found on the X chromosome, are at considerably greater risk of developing Alzheimer's disease.

12 Jan 2009

FORMA Therapeutics to collaborate with Novartis on inhibitors

FORMA Therapeutics has announced that it has entered into a license and option agreement through the Novartis Option Fund.

12 Jan 2009

New drugs have longer clinical development times despite faster FDA review

While the U.S. Food and Drug Administration Drug has quickened review and approval of new medicines, the complex nature of diseases for which new therapeutics are being developed has resulted in longer clinical development times, according to the Tufts Center for the Study of Drug Development.

8 Jan 2009

Liquidia Technologies to collaborate with Abbott on siRNA therapeutics

Liquidia Technologies, Inc. announced today that it has entered into a collaboration and license agreement with Abbott to develop PRINT nanoparticles for the delivery of siRNA-based therapeutics. Liquidia's PRINT technology offers the ability to fabricate nanoparticles of precisely defined size, shape, surface chemistry, and composition, which offers the potential to develop safer and more effective therapies.

7 Jan 2009

Chimerix completes phase I study and starts phase II multi-dose trial for CMX001

Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, has announced that the Company has completed a single and multi-dose Phase I study of CMX001 in healthy volunteers.

6 Jan 2009

Phase 3 trial begins for Gammagard liquid plus rHuPH20 in primary immunodeficiency patients

Baxter International Inc. and Halozyme Therapeutics, Inc. gas announced the start of a Phase 3 clinical trial of Baxter's Gammagard Liquid [Immune Globulin Intravenous] 10% (IGIV), marketed as KIOVIG in the European Union, with Halozyme's recombinant human hyaluronidase enzyme (rHuPH20, Enhanze Technology) for the treatment of primary immunodeficiency (PID).

From Baxter International Inc. 5 Jan 2009